NEW YORK, July 8-Daiichi Pharmaceuticals has arranged a nonexclusive subscription to Inpharmatica's Biopendium protein database, Inpharmatica said yesterday.
The specific financial conditions of the agreement were not disclosed.
Biopendium includes protein sequences and structures, as well as tools to predict protein/ligand interactions and compare sequence patterns. It is designed for target discovery and lead compound identification.
Daiichi is Inpharmatica's first Japanese client, joining subscribers such as Pfizer and Genentech.
Inpharmatica is based in London.